Summary statistics - quantitative results

EQA round: CRP2/23 - C-Reactive Protein

Deadline: 19.5.2023

Setup: groups - manufacturer of kit; minimal size of the groups n = 5

RoM = robust average
SD = standard deviation
CV = coefficient of variation
N_{tot} = total number of the results
N_{out} = number of the results removed before calculation

AV = assigned value
CVP = consensus of all participants
U_{AV} = expanded uncertainty of the assigned value (k = 2)

D_{max} = acceptable difference
LL = lower limit
UL = upper limit
N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]
(100) **C-reactive protein**	[mg/L]				171								171	168	98
Sample A		26,1	2	7,5	171		CVP	26,1	0,37	24%	19,8	32,4	171	168	98
(1) Abbott		27,5	0,75	2,7	48	0							48		
(49) BioVendor		28,2	3,2	11	5	0							5		
(58) Beckman Coulter (AU)		24,5	1,3	5,2	18	0							18		
(60) Roche		24,9	0,9	3,6	60	0							60		
(162) Siemens (Atellica)		28,5	0,74	2,6	8	0							8		
(177) Mindray		27,1	0,74	2,7	5	0							5		
(178) DiaSys		25,2	3	12	5	0							5		
Other					22	1	1x 0, 4x 12, 1x 40, 1x 61, 2x 70, 1x 73, 2x 116, 2x 149, 1x 152, 2x 166, 4x 179, 1x 200						22		
Sample B		55,1	4,5	8,2	171		CVP	55,1	0,84	24%	41,8	68,4	171	169	99
(1) Abbott		57,5	2,2	3,8	48	0							48		
(49) BioVendor		59,5	8,5	14	5	0							5		
(58) Beckman Coulter (AU)		61,9	2,4	3,9	18	0							18		
(60) Roche		51,5	2,3	4,4	60	0							60		
(162) Siemens (Atellica)		54,6	1,5	2,7	8	0							8		
(177) Mindray		54,4	1,4	2,6	5	0							5		
(178) DiaSys		52,7	1,8	3,4	5	0							5		
Other					22	0	1x 0, 4x 12, 1x 40, 1x 61, 2x 70, 1x 73, 2x 116, 2x 149, 1x 152, 2x 166, 4x 179, 1x 200						22		